These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 31778621

  • 1. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A, Shi N, Zhu B, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Murage MJ.
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [Abstract] [Full Text] [Related]

  • 2. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM.
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [Abstract] [Full Text] [Related]

  • 3. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A, Burge R, Malatestinic W, Brnabic A, Guo J, Janardhanan M, Zhu B.
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [Abstract] [Full Text] [Related]

  • 4. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
    Blauvelt A, Shi N, Murage MJ, Kern SA, Somani N, Burge R, Ridenour TL, Lew CR, Zimmerman NM, Zhu B.
    J Med Econ; 2022 Jan; 25(1):741-749. PubMed ID: 35615978
    [Abstract] [Full Text] [Related]

  • 5. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ, Princic N, Park J, Malatestinic WN, Zhu B, Atiya B, Kern SA, Stenger KB, Sprabery AT, Ogdie A.
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [Abstract] [Full Text] [Related]

  • 6. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA, Zhu B, Guo J, Nikai E, Ojeh C, Malatestinic W, Goldblum O, Kornberg LJ, Wu JJ.
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
    Blauvelt A, Shi N, Somani N, Burge R, Zhu B, Ridenour T, Kern S, Lew C, Zimmerman N, Murage M.
    Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
    [Abstract] [Full Text] [Related]

  • 8. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM, Brixner D, Rubin DT, Mease P, Liu H, Davis M, Mittal M.
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [Abstract] [Full Text] [Related]

  • 9. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, Kistler K, Fraeman K, Johnston J, Hawley LL, Sicignano N, Araujo A.
    J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
    [Abstract] [Full Text] [Related]

  • 10. Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
    Blauvelt A, Shi N, Burge R, Atiya B, Zhu B, Somani N, Ridenour T, Lew CR, Zimmerman NM, Murage MJ.
    Pharmacoecon Open; 2022 Nov; 6(6):871-880. PubMed ID: 36155891
    [Abstract] [Full Text] [Related]

  • 11. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [Abstract] [Full Text] [Related]

  • 12. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases.
    Leonardi C, Zhu B, Malatestinic WN, Eastman WJ, Guo J, Murage MJ, Choong CK, Burge R, Blauvelt A.
    Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
    [Abstract] [Full Text] [Related]

  • 13. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [Abstract] [Full Text] [Related]

  • 14. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
    Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y.
    J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
    Blauvelt A, Shi N, Murage M, Ridenour T, Lew C, Somani N, Zhu B, Zimmerman N, Kern S, Burge R.
    J Drugs Dermatol; 2022 Apr 01; 21(4):399-407. PubMed ID: 35389589
    [Abstract] [Full Text] [Related]

  • 16. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.
    J Manag Care Spec Pharm; 2018 Apr 01; 24(4):344-352. PubMed ID: 29578852
    [Abstract] [Full Text] [Related]

  • 17. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ, Keyloun KR, Higa S, Park J, Bonafede M, Gillard P, Jain R.
    J Manag Care Spec Pharm; 2022 Dec 01; 28(12):1335-1343. PubMed ID: 36427344
    [Abstract] [Full Text] [Related]

  • 18. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.
    Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh JA.
    J Manag Care Spec Pharm; 2023 Jan 01; 29(1):24-35. PubMed ID: 36318701
    [Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL.
    J Manag Care Spec Pharm; 2018 Dec 01; 24(12):1210-1217. PubMed ID: 30479197
    [Abstract] [Full Text] [Related]

  • 20. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR, Sandhu S, George DJ, Chi KN, Saad F, Thiery-Vuillemin A, Stàhl O, Olmos D, Danila DC, Gafanov R, Castro E, Moon H, Joshua AM, Mason GE, Espina BM, Liu Y, Lopez-Gitlitz A, Francis P, Bevans KB, Fizazi K.
    J Manag Care Spec Pharm; 2023 Jul 01; 29(7):758-768. PubMed ID: 37404070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.